Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Vinorelbine

Cisplatin

Erlotinib Hydrochloride

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Tyrosine

Erlotinib

cis-platinum

Changli Wang

This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.

Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation

2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year.

Disease free survival is defined as the time from randomization to disease recurrence or death which comes first.

Overall survival is defined as the time from randomization to death.

The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS)

Roche Pharma AG

Tianjin Medical University Cancer Institute and Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	NCT01683175	Non-small Cell ...	Erlotinib cis-platinum Vinorelbine	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital

Spots Global Cancer Trial Database for iiia nsclc

Every month we try and update this database with for iiia nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for iiia nsclc

Every month we try and update this database with for iiia nsclc cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for iiia nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.